OORTP

Oort Pharma is a biotechnology company focused on developing small molecule inhibitors of O-GlcNAc transferase (OGT). OGT is an enzyme that modifies proteins with a single sugar molecule, O-GlcNAc, which plays a critical role in cellular signaling and metabolism. The company's platform targets the dysregulation of O-GlcNAcylation, which is linked to various diseases including cancer, inflammatory disorders, and neurodegenerative conditions. Oort Pharma aims to leverage its expertise in OGT biology to create first-in-class therapeutics for patients with high unmet medical needs. Based in Cambridge, UK, the company was founded on pioneering research from the University of Oxford and is supported by leading life science investors.